Literature DB >> 15273707

Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect.

B Glass1, M Nickelsen, P Dreger, A Claviez, J Hasenkamp, G Wulf, L Trümper, N Schmitz.   

Abstract

In patients with poor-risk relapse of aggressive lymphoma, reduced-intensity conditioning followed by allogeneic PBSCT may have its limitations because of rapid regrowth of the tumor. We tried to address this problem by intermediate-intensity conditioning followed by allogeneic SCT. A total of 21 patients received fludarabine, busulfan and cyclophosphamide prior to allogeneic SCT. In the first 10 patients, GVHD prophylaxis by CD34+ selection of the grafts was employed (group I). The next 11 patients received nonmanipulated grafts and mycophenolat mofetil plus cyclosporinA (group II). In group I, no GVHD was observed. In contrast, patients in group II had a significant risk of acute GVHD (aGVHD) (six patients with grade II-IV acute GVHD). However, in group I, all surviving patients progressed within 9 months. In contrast, eight of nine surviving patients of group II remain in remission after a median observation time of 10.5 months (range 4-22 months). Survival differed significantly between the groups (P=0.004). Multivariate analysis identified intensive GVHD prophylaxis as important risk factor for survival. These results support the existence of a clinically relevant GVL effect in aggressive lymphoma. T-cell depletion (or CD34 selection) of grafts is not recommended in patients with poor-risk aggressive NHL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273707     DOI: 10.1038/sj.bmt.1704600

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

Review 1.  Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Koen van Besien
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

2.  Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy.

Authors:  Christoph Johannes Szuszies; Justin Hasenkamp; Wolfram Jung; Raphael Koch; Lorenz Trümper; Gerald G Wulf
Journal:  Int J Hematol       Date:  2014-09-26       Impact factor: 2.490

Review 3.  Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

Authors:  Peter Dreger; Timothy S Fenske; Silvia Montoto; Marcelo C Pasquini; Anna Sureda; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-07       Impact factor: 5.742

4.  Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR.

Authors:  Gregory A Hale; Smriti Shrestha; Jennifer Le-Rademacher; Linda J Burns; John Gibson; David J Inwards; Cesar O Freytes; Brian J Bolwell; Jack W Hsu; Shimon Slavin; Luis Isola; David A Rizzieri; Robert Peter Gale; Ginna G Laport; Silvia Montoto; Hillard M Lazarus; Parameswaran N Hari
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-07       Impact factor: 5.742

5.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

6.  Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma.

Authors:  Michael Schmitt; Rudolf Trenschel; Herbert G Sayer; Catarina Schneider; Aenne Glass; Inken Hilgendorf; Anne Treschl; Christian Junghanss; Kersten Borchert; Michael Koenigsmann; Jochen Casper; Dietrich W Beelen; Mathias Freund; Christoph Kahl
Journal:  Mol Clin Oncol       Date:  2014-06-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.